KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Cash from Financing Activities: 2010-2025

Historic Cash from Financing Activities for Arbutus Biopharma (ABUS) over the last 16 years, with Sep 2025 value amounting to $844,000.

  • Arbutus Biopharma's Cash from Financing Activities fell 52.45% to $844,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year decrease of 89.88%. This contributed to the annual value of $52.0 million for FY2024, which is 69.66% up from last year.
  • Per Arbutus Biopharma's latest filing, its Cash from Financing Activities stood at $844,000 for Q3 2025, which was up 86.31% from $453,000 recorded in Q2 2025.
  • In the past 5 years, Arbutus Biopharma's Cash from Financing Activities ranged from a high of $59.1 million in Q4 2021 and a low of $113,000 during Q2 2022.
  • For the 3-year period, Arbutus Biopharma's Cash from Financing Activities averaged around $7.9 million, with its median value being $2.8 million (2025).
  • Per our database at Business Quant, Arbutus Biopharma's Cash from Financing Activities skyrocketed by 4,096.46% in 2023 and then crashed by 98.14% in 2025.
  • Quarterly analysis of 5 years shows Arbutus Biopharma's Cash from Financing Activities stood at $59.1 million in 2021, then crashed by 81.25% to $11.1 million in 2022, then tumbled by 65.65% to $3.8 million in 2023, then tumbled by 62.67% to $1.4 million in 2024, then slumped by 52.45% to $844,000 in 2025.
  • Its Cash from Financing Activities was $844,000 in Q3 2025, compared to $453,000 in Q2 2025 and $2.8 million in Q1 2025.